Select a Region North America

World Orphan Drug Congress USA

EVERSANA™ is a proud to sponsor the World Orphan Drug Congress USA held at the Hynes Center in Boston, Massachusetts July 11-13. 2022.  Visit booth #413 or schedule a meeting with EVERSANA’s experts in rare diseases, patient services, data and analytics and commercialization services to learn how EVERSANA leads the way in simplifying complex rare disease patient journeys.  

EVERSANA’s Rare Disease Expertise  

With over 7,000 distinct rare and genetic diseases affecting 400+ million individuals, the average time to diagnosis still remains approximately 7 years. In response, EVERSANA has developed innovative, end-to-end strategies to assure patients are identified, diagnosed, onboarded and remain adherent to their treatment plans. 

Rare and orphan drug manufacturers are becoming increasingly aware that new models and new approaches are needed for a successful product launch. With experience in 25 disease states, EVERSANA™ COMPLETE Commercialization is uniquely positioned to remove friction in commercialization to enable an accelerated path to market introduction for critical therapies. Powered by artificial intelligence (AI), machine learning (ML) and Data & Analytics, our end-to-end model supplies predictive analytics to reach patients, improves access to therapy and facilitates positive outcomes.  

 By leveraging data and AI capabilities of ACTICS by EVERSANA™ across the patient journey, EVERSANA can predict patient switching behaviors that impact adherence and engagement. This information also powers the optimization of our hub and affordability programs and deploys the “next best action” for each patient, leading to up to a 50% patient adherence improvement over a traditional hub program. 

EVERSANA’s patient services models simplify and expedite the patient journey. Our hub accelerates patient onboarding by supplying real time eligibility determination, self-enrollment with support options, ePa electronic benefit verification (eBV), (ePA), co-pay eligibility and e-prescribing. Our specialty pharmacy model connects patients, providers and payers to offer direct-to-patient dispensing and administration. In addition, data-driven patient profiling can determine customized outreach to provide education and deliver white-glove support to patients, driving brand loyalty and adherence. 

Speaking Sessions Featuring EVERSANA Experts  

Be sure to attend the following sessions featuring EVERSANA’s Maria Kirsch, General Manager, Patient Services, Simon Andrews, Senior Vice President, Head of Analytics, and Scott Snyder, Chief Digital Officer. 

The Digital Hub: Balancing High-Tech and High-Touch Solutions to Eliminate Access, Affordability and Adherence Barriers of Rare Disease Patients 

Fireside Chat Tuesday, July 12 – 11:35AM EST 

EVERSANA Participants: 

  • Maria Kirsch, General Manager, Patient Services 

Making Sense Out of Data to Master Patient-Finding

Fireside Chat Tuesday, July 12 – 3:35PM EST 

EVERSANA Participants: 

  • Simon Andrews, Senior Vice President, Head of Analytics

Data & Innovation Keynote Panel: Use of Real-World Data & AI for Rare Diseases 

Key Note Panel Tuesday, July 12 – 4:50PM EST 

Where are key areas of opportunity in product development, patient access and commercialization?  

EVERSANA Participants: 

  • Scott Snyder, Chief Digital Officer 

Join EVERSANA and other leaders in the industry at the upcoming WODC as we advance the conversation on: 

  • Patient data 
  • Next generation therapies  
  • Payers 
  • Clinical development & regulatory 
  • Commercial 
  • Rare disease advisory world 
  • Global market & patient access 
  • Pricing & Reimbursement 
  • Pitch & partner 
  • Advancing therapies – Manufacturing  
  • Advancing therapies – Clinical development 
  • Rare oncology 
  • Advanced therapies – Commercialization  
  • Digital health & Artificial intelligence 
  • Diagnosis 
  • Discovery   

About World Orphan Drug Congress 

The World Orphan Drug Congress, the most comprehensive program and inclusive gathering of rare disease stakeholders, brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies. 

Visit booth #413 or schedule a meeting with EVERSANA’s rare disease experts today.